Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prolactin receptor antagonists.

Ameae M Walker1

  • 1Division of Biomedical Sciences, University of California, Riverside, CA 92521, USA. Ameae.Walker@ucr.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|May 19, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Knockdown of the long isoform of the prolactin receptor selectively targets pathogenic immune cells in systemic lupus erythematosus and averts glomerular pathology.

bioRxiv : the preprint server for biology·2026
Same author

The Ability of Neonatal Mice to Develop Immunity to <i>Mycobacterium tuberculosis</i> Shows Sex Differences, with Females Displaying Evidence of an Enhanced Immune Response.

Journal of cellular immunology·2025
Same author

B lymphoproliferative diseases: Effective treatment, inhibited progression, and potential cures through isoform-specific targeting of the prolactin receptor.

Vitamins and hormones·2025
Same author

Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms.

Communications biology·2023
Same author

A cautionary tale: Alien prolactins may induce lesser, no, or opposite effects to homologous hormone!

Journal of neuroendocrinology·2022
Same author

Tumor cell-derived asymmetric dimethylarginine regulates macrophage functions and polarization.

Cancer cell international·2022
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Researchers are developing prolactin receptor (PRLR) antagonists as potential cancer therapeutics. A novel approach involves a molecule that acts as both an antagonist and agonist, inhibiting growth while promoting cell death pathways.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Prolactin receptor (PRLR) antagonists are being investigated for cancer therapy.
  • Current strategies include pure antagonists and combination therapies.
  • The goal is to develop effective treatments for breast, prostate, and other cancers.

Purpose of the Study:

  • To explore novel therapeutic strategies targeting the prolactin receptor.
  • To develop a combined antagonist/agonist molecule for enhanced anti-cancer effects.

Main Methods:

  • Development of a mimic of the natural prolactin (PRL) growth antagonist.
  • Characterization of the molecule's dual antagonist/agonist properties.

Main Results:

Related Experiment Videos

  • The developed molecule inhibits PRLR signaling pathways associated with cancer growth.
  • The molecule also activates signaling pathways crucial for cell-cycle control, differentiation, and apoptosis.

    • Conclusions:

    • A novel PRLR antagonist/agonist molecule shows promise as a potential anti-cancer therapeutic.
    • This dual-action approach may offer improved efficacy compared to pure antagonists.